Table of Contents

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Insulin Delivery Devices Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in the prevalence of diabetes globally
3.2.1.2. Increasing geriatric population
3.2.1.3. Favorable government reimbursement scenario
3.2.1.4. Increasing awareness about diabetes preventive care
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulatory framework
3.2.2.2. High cost of devices
3.3. Insulin Delivery Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Insulin Delivery Devices Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Insulin Delivery Devices Product Market Movement Analysis
4.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by Product, 2023-2032 (USD Million)
4.4. Insulin Pens
4.4.1. Insulin pens market estimates and forecasts 2023-2032 (USD Million)
4.4.2. Reusable Insulin Pens
4.4.2.1. Reusable insulin pens market estimates and forecasts 2023-2032 (USD Million)
4.4.3. Disposable Insulin Pens
4.4.3.1. Disposable insulin pens market estimates and forecasts 2023-2032 (USD Million)
4.5. Insulin Pumps
4.5.1. Insulin pumps market estimates and forecasts 2023-2032 (USD Million)
4.5.2. Patch Pumps
4.5.2.1. Patch pumps market estimates and forecasts 2023-2032 (USD Million)
4.5.3. Tethered Pumps
4.5.3.1. Tethered pumps market estimates and forecasts 2023-2032 (USD Million)
4.6. Insulin Pen Needles
4.6.1. Insulin pen needles market estimates and forecasts 2023-2032 (USD Million)
4.6.2. Standard Pen Needles
4.6.2.1. Standard pen needles market estimates and forecasts 2023-2032 (USD Million)
4.6.3. Safety Pen Needles
4.6.3.1. Safety pen needles market estimates and forecasts 2023-2032 (USD Million)
4.7. Insulin Syringes
4.8. Other Products

Chapter 5. Insulin Delivery Devices Market: End Use Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Insulin Delivery Devices End Use Market Movement Analysis
5.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by End Use, 2023-2032 (USD Million)
5.4. Hospitals & Clinics
5.4.1. Hospitals & clinics market estimates and forecasts 2023-2032 (USD Million)
5.5. Homecare
5.5.1. Homecare market estimates and forecasts 2023-2032 (USD Million)
5.6. Other End User
5.6.1. Other End Users market estimates and forecasts 2023-2032 (USD Million)

Chapter 6. Insulin Delivery Devices Market: Regional Estimates & Trend Analysis By Product, End Use

6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Competitive scenario
6.5.1.3. Regulatory framework
6.5.1.4. Reimbursement structure
6.5.1.5. U.S. market estimates and forecasts 2023-2032 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Competitive scenario
6.5.2.3. Regulatory framework
6.5.2.4. Reimbursement structure
6.5.2.5. Canada market estimates and forecasts 2023-2032 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Competitive scenario
6.5.3.3. Regulatory framework
6.5.3.4. Reimbursement structure
6.5.3.5. Canada market estimates and forecasts 2023-2032 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Competitive scenario
6.6.1.3. Regulatory framework
6.6.1.4. Reimbursement structure
6.6.1.5. UK market estimates and forecasts 2023-2032 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Competitive scenario
6.6.2.3. Regulatory framework
6.6.2.4. Reimbursement structure
6.6.2.5. Germany market estimates and forecasts 2023-2032 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Competitive scenario
6.6.3.3. Regulatory framework
6.6.3.4. Reimbursement structure
6.6.3.5. France market estimates and forecasts 2023-2032 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Competitive scenario
6.6.4.3. Regulatory framework
6.6.4.4. Reimbursement structure
6.6.4.5. Italy market estimates and forecasts 2023-2032 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Competitive scenario
6.6.5.3. Regulatory framework
6.6.5.4. Reimbursement structure
6.6.5.5. Spain market estimates and forecasts 2023-2032 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Competitive scenario
6.6.6.3. Regulatory framework
6.6.6.4. Reimbursement structure
6.6.6.5. Norway market estimates and forecasts 2023-2032 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Competitive scenario
6.6.7.3. Regulatory framework
6.6.7.4. Reimbursement structure
6.6.7.5. Sweden market estimates and forecasts 2023-2032 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Competitive scenario
6.6.8.3. Regulatory framework
6.6.8.4. Reimbursement structure
6.6.8.5. Denmark market estimates and forecasts 2023-2032 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Competitive scenario
6.7.1.3. Regulatory framework
6.7.1.4. Reimbursement structure
6.7.1.5. Japan market estimates and forecasts 2023-2032 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Competitive scenario
6.7.2.3. Regulatory framework
6.7.2.4. Reimbursement structure
6.7.2.5. China market estimates and forecasts 2023-2032 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Competitive scenario
6.7.3.3. Regulatory framework
6.7.3.4. Reimbursement structure
6.7.3.5. India market estimates and forecasts 2023-2032 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Competitive scenario
6.7.4.3. Regulatory framework
6.7.4.4. Reimbursement structure
6.7.4.5. Australia market estimates and forecasts 2023-2032 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Competitive scenario
6.7.5.3. Regulatory framework
6.7.5.4. Reimbursement structure
6.7.5.5. South Korea market estimates and forecasts 2023-2032 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Competitive scenario
6.7.6.3. Regulatory framework
6.7.6.4. Reimbursement structure
6.7.6.5. Thailand market estimates and forecasts 2023-2032 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Competitive scenario
6.8.1.3. Regulatory framework
6.8.1.4. Reimbursement structure
6.8.1.5. Brazil market estimates and forecasts 2023-2032 (USD Million)
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Competitive scenario
6.8.2.3. Regulatory framework
6.8.2.4. Reimbursement structure
6.8.2.5. Argentina market estimates and forecasts 2023-2032 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Competitive scenario
6.9.1.3. Regulatory framework
6.9.1.4. Reimbursement structure
6.9.1.5. South Africa market estimates and forecasts 2023-2032 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Competitive scenario
6.9.2.3. Regulatory framework
6.9.2.4. Reimbursement structure
6.9.2.5. Saudi Arabia market estimates and forecasts 2023-2032 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Competitive scenario
6.9.3.3. Regulatory framework
6.9.3.4. Reimbursement structure
6.9.3.5. UAE market estimates and forecasts 2023-2032 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Competitive scenario
6.9.4.3. Regulatory framework
6.9.4.4. Reimbursement structure
6.9.4.5. Kuwait market estimates and forecasts 2023-2032 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Key company market share analysis, 2023
7.4. Company Position Analysis
7.5. Company Categorization (Emerging Players, Innovators and Leaders
7.6. Company Profiles
7.6.1. Novo Nordisk A/S
7.6.1.1. Company overview
7.6.1.2. Financial performance
7.6.1.3. Product benchmarking
7.6.1.4. Strategic initiatives
7.6.2. Sanofi
7.6.2.1. Company overview
7.6.2.2. Financial performance
7.6.2.3. Product benchmarking
7.6.2.4. Strategic initiatives
7.6.3. Eli Lilly and Company
7.6.3.1. Company overview
7.6.3.2. Financial performance
7.6.3.3. Product benchmarking
7.6.3.4. Strategic initiatives
7.6.4. Ypsomed AG
7.6.4.1. Company overview
7.6.4.2. Financial performance
7.6.4.3. Product benchmarking
7.6.4.4. Strategic initiatives
7.6.5. Medtronic
7.6.5.1. Company overview
7.6.5.2. Financial performance
7.6.5.3. Product benchmarking
7.6.5.4. Strategic initiatives
7.6.6. Insulet Corporation
7.6.6.1. Company overview
7.6.6.2. Financial performance
7.6.6.3. Product benchmarking
7.6.6.4. Strategic initiatives
7.6.7. B. Braun SE
7.6.7.1. Company overview
7.6.7.2. Financial performance
7.6.7.3. Product benchmarking
7.6.7.4. Strategic initiatives
7.6.8. Owen Mumford Ltd.
7.6.8.1. Company overview
7.6.8.2. Financial performance
7.6.8.3. Product benchmarking
7.6.8.4. Strategic initiatives
7.6.9. Tandem Diabetes Care, Inc.
7.6.9.1. Company overview
7.6.9.2. Financial performance
7.6.9.3. Product benchmarking
7.6.9.4. Strategic initiatives
7.6.9.5. Company overview
7.6.10. BD
7.6.10.1. Company overview
7.6.10.2. Financial performance
7.6.10.3. Product benchmarking
7.6.10.4. Strategic initiatives
7.6.10.5. Company overview